Win ratio analysis of the LANDMARK trial
Tobe, Akihiro van Royen, Niels Amat-Santos, Ignacio J. Hudec, Martin Bunc, Matjaz Ijsselmuiden, Alexander Pomar, Jose Luis Rosseel, Liesbeth Gamal Amr Iqbal, Javaid
Tobe, Akihiro
van Royen, Niels
Amat-Santos, Ignacio J.
Hudec, Martin
Bunc, Matjaz
Ijsselmuiden, Alexander
Pomar, Jose Luis
Rosseel, Liesbeth
Gamal Amr
Iqbal, Javaid
Loading...
Publication Date
2025-05-23
Type
journal article
Downloads
Citation
Tobe, Akihiro, van Royen, Niels, Amat-Santos, Ignacio J., Hudec, Martin, Bunc, Matjaz, Ijsselmuiden, Alexander, et al (2025). Win ratio analysis of the LANDMARK trial. American Heart Journal, 289, 1-5. https://doi.org/10.1016/j.ahj.2025.04.024
Abstract
The LANDMARK trial reported the non-inferiority of the Myval transcatheter heart valve (THV) series compared with the contemporary standard THV series (Sapien and Evolut) for a 30-day composite endpoint in patients with severe aortic stenosis. This exploratory study compared the performance of the Myval THV series with the contemporary THV series using the win ratio analysis.
Funder
Publisher
Elsevier
Publisher DOI
Rights
Attribution 4.0 International